Yoon Hong Man, Kim Young-Woo, Nam Byung Ho, Reim Daniel, Eom Bang Wool, Park Ji Yeon, Ryu Keun Won
Hong Man Yoon, Young-Woo Kim, Daniel Reim, Bang Wool Eom, Ji Yeon Park, Keun Won Ryu, Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang-si 410-769, South Korea.
World J Gastroenterol. 2014 Feb 21;20(7):1852-7. doi: 10.3748/wjg.v20.i7.1852.
To determine whether the application of post-operative intravenous (IV)-iron for acute isovolemic anemia after gastrectomy for cancer may be effective.
Among 2078 gastric cancer patients who underwent surgery between February 2007 and August 2009 at the National Cancer Center Korea, 368 patients developed post-operative anemia [hemoglobin-(Hb)-level < 9 g/dL] within the first postoperative week. Patients requiring transfusions were excluded. IV-iron was administered to 63 patients (iron group). Sixty patients were observed without treatment (observation group). The clinical outcomes of the groups were compared concerning clinicopathologic data, morbidity, and changes in Hb levels using Fisher's exact test, Student's t-test and the Z-test.
The initial Hb level was higher in the iron group than in the observation group (7.3 ± 1.0 g/dL vs 8.4 ± 0.5 g/dL, P < 0.001). The slope of the changes in the Hb level was significantly higher in the iron group than in the observation group (0.648 ± 0.054 vs 0.349 ± 0.038, P < 0.001). The Hb level 1 and 3 mo post-operatively increased from 10.7 ± 1.3 to 11.9 ± 1.3 g/dL in the iron group (P = 0.033) and from 10.1 ± 1.0 to 10.8 ± 1.4 g/dL in the observation group (P < 0.001). The postoperative hospital stay was significantly longer in the iron group than in the observation group (10.5 ± 6.8 d vs 7.6 ± 5.5 d, P = 0.011). There were no significant differences in the major and surgical complications between the groups (6.3% vs 13.3%, P = 0.192; 9.5% vs 3.3%, P = 0.164).
IV-iron supplementation may be an effective treatment for post-operative isovolemic post-gastrectomy anemia and may be a better alternative than observation.
确定胃癌胃切除术后急性等容性贫血患者应用术后静脉注射铁剂是否有效。
在2007年2月至2009年8月于韩国国立癌症中心接受手术的2078例胃癌患者中,368例患者在术后第一周内出现术后贫血(血红蛋白-Hb-水平<9 g/dL)。排除需要输血的患者。63例患者接受静脉注射铁剂治疗(铁剂组)。60例患者未接受治疗(观察组)。使用Fisher精确检验、Student t检验和Z检验比较两组的临床结局,包括临床病理数据、发病率和Hb水平变化。
铁剂组的初始Hb水平高于观察组(7.3±1.0 g/dL对8.4±0.5 g/dL,P<0.001)。铁剂组Hb水平变化斜率显著高于观察组(0.648±0.054对0.349±0.038,P<0.001)。铁剂组术后1个月和3个月时Hb水平从10.7±1.3 g/dL升至11.9±1.3 g/dL(P=0.033),观察组从10.1±1.0 g/dL升至10.8±1.4 g/dL(P<0.001)。铁剂组术后住院时间显著长于观察组(10.5±6.8天对7.6±5.5天,P=0.011)。两组之间的主要并发症和手术并发症无显著差异(6.3%对13.3%,P=0.192;9.5%对3.3%,P=0.164)。
静脉补充铁剂可能是治疗胃癌胃切除术后等容性贫血的有效方法,可能比观察更具优势。